Print this page

Fresenius Kabi AG

Fresenius Kabi at a glance

Our product portfolio comprises a comprehensive range of I.V generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products.  Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems.

 


With our corporate philosophy of "caring for life", we are committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face. 

 

Fresenius Kabi employs around 35,000 people worldwide.

 

In 2016 the company reported sales of more than €6 billion.
Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA health care group.

 

Key Figures

 € in millions

2016

2015 

 Change

 Sales

 6,007

5,950

1%

 EBITDA1

 1,479

 1,446

 2%

 EBIT1

 1,224

 1,189

 3%

 Net Income2

 716

 669

 7%

 Employees (Dec 31)

 34,917

 33,195

 5%

1  2015 before special items

2  Net income attributable to shareholders

    of Fresenius Kabi AG; 

    2015 before special items